

CorMedix Inc.  
Form 4  
February 24, 2016

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lefkowitz Steven W

(Last) (First) (Middle)

C/O CORMEDIX INC., 1430 US  
HIGHWAY 206, SUITE 200

(Street)

BEDMINSTER, NJ US 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CorMedix Inc. [CRMD]

3. Date of Earliest Transaction  
(Month/Day/Year)  
02/22/2016

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)           | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4)            |
|---|--------------------------------------|--|--------------------------------|---|---|--|--|
|   |                                      |  |                                | (A) or (D)  | Code V Amount (D) Price   |  |  |
| Common Stock, \$0.001 par value per share |                                      |  |                                |   | 147,399   | D  |  |
| Common Stock, \$0.001 par value per share |                                      |  |                                |   | 174,741   | I <sup>(1)</sup>   | Wade Capital Corporation Money Purchase Plan |
| Common Stock,                             |                                      |  |                                |   | 10,000  | I <sup>(1)</sup>   | Reporting Person's Wife                      |

\$0.001 par value per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3)        | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|---|--|--------------------------------------|--|--------------------------------|---|--|---|
|   |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable Expiration Date                         | Title Amount Number Shares                                    |
| Stock Option (right to buy)                       | \$ 2.02  |                                      |  |                                |   | (2) 01/09/2024   | Common Stock, \$0.001 par value per share 200,000             |
| Stock Option (right to buy)                       | \$ 2.02  |                                      |  |                                |   | (7) 01/09/2024   | Common Stock, \$0.001 par value per share 30,000              |
| Swries C-3 Non-Voting Convertible Preferred Stock | \$ 1   |                                      |  |                                |   | (3) (3)  | Common Stock, \$0.001 par value per share 45,000              |
| Warrant (right to purchase Common Stock)          | \$ 0.9 (4)   |                                      |  |                                |   | 01/08/2015 01/08/2020                                    | Common Stock, \$0.001 par value per share 22,500              |
| Series C-3 Non-Voting Convertible Preferred Stock | \$ 1   |                                      |  |                                |   | (4) (4)  | Common Stock, \$0.001 par value per share 30,000              |

|  |                       |            |  |   |        |                |            |   |         |
|--|-----------------------|------------|--|---|--------|----------------|------------|---|---------|
| Warrant<br>(right to<br>purchase<br>Common<br>Stock) | \$ 0.9 <sup>(4)</sup> |            |  |   |        | 01/08/2015     | 01/08/2020 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 15,000  |
| Stock<br>Option<br>(right to<br>buy)                 | \$ 0.9                |            |  |   |        | <sup>(5)</sup> | 03/20/2023 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 120,000 |
| Stock<br>Option<br>(right to<br>buy)                 | \$ 0.68               |            |  |   |        | <sup>(6)</sup> | 12/05/2022 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 150,000 |
| Stock<br>Option<br>(right to<br>buy)                 | \$ 1.1                |            |  |   |        | <sup>(8)</sup> | 08/11/2021 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 30,000  |
| Stock<br>Option<br>(right to<br>buy)                 | \$ 5.62               |            |  |   |        | <sup>(7)</sup> | 03/01/2025 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 50,000  |
| Stock<br>Option<br>(right to<br>buy)                 | \$ 1.91               | 02/22/2016 |  | A | 75,000 | <sup>(7)</sup> | 02/21/2026 | Common<br>Stock,<br>\$0.001<br>par value<br>per share | 75,000  |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| Lefkowitz Steven W<br>C/O CORMEDIX INC.<br>1430 US HIGHWAY 206, SUITE 200<br>BEDMINSTER, NJ US 07921 | X             |           |         |       |

## Signatures

/s/Alexander M. Donaldson by Power of  
Attorney

02/24/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- (2) The options vested 100% on January 10, 2014.
- (3) On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (4) On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, \$0.001 par value per share at a conversion price of \$1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of \$1.25 per share. The warrant exercise price was decreased from \$1.25 per share to \$0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of \$10.00 per share for each share of Series C-3 Preferred Stock.
- (5) These options vest quarterly over two years beginning June 13, 2013.
- (6) These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- (7) The options vest in full on the first anniversary of the date of grant.
- (8) The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.